InMed Pharmaceuticals (INM) EBITDA (2021 - 2026)

InMed Pharmaceuticals has reported EBITDA for 6 years, with the latest figure at -$2.8 million in Q1 2026.

• On a quarterly basis, EBITDA fell 47.26% year-over-year to -$2.8 million in Q1 2026; TTM through Mar 2026 was -$9.2 million, a 16.27% decrease from a year earlier, with the FY2025 full-year figure at -$7.9 million, up 3.1% from the prior year.
• EBITDA was -$2.8 million for Q1 2026 at InMed Pharmaceuticals, down from -$2.1 million in the prior quarter.
• The five-year high for EBITDA was -$472234.0 in Q2 2023, with the low at -$6.5 million in Q2 2022.
• Average EBITDA over 5 years is -$2.4 million, with a median of -$2.1 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: EBITDA soared 92.76% in 2023, then tumbled 329.61% in 2024.
• Over 5 years, EBITDA stood at -$2.2 million in 2022, then gained by 26.07% to -$1.6 million in 2023, then plunged by 37.47% to -$2.2 million in 2024, then gained by 6.21% to -$2.1 million in 2025, then slumped by 32.78% to -$2.8 million in 2026.
• The last three EBITDA figures came in at -$2.8 million (Q1 2026), -$2.1 million (Q4 2025), and -$1.8 million (Q3 2025), per Business Quant data.